Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

A novel role for dopamine signaling in the pathogenesis of bone loss from the atypical antipsychotic drug risperidone in female mice.

Motyl KJ, Beauchemin M, Barlow D, Le PT, Nagano K, Treyball A, Contractor A, Baron R, Rosen CJ, Houseknecht KL.

Bone. 2017 Oct;103:168-176. doi: 10.1016/j.bone.2017.07.008. Epub 2017 Jul 6.

PMID:
28689816
2.

Advancing the Quality of Pediatric Antipsychotic Use: Maybe It Takes a PAL.

Zito JM.

Health Serv Res. 2017 Apr;52(2):555-560. doi: 10.1111/1475-6773.12671. No abstract available.

PMID:
28297076
3.

Impulsive Aggression as a Comorbidity of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents.

Saylor KE, Amann BH.

J Child Adolesc Psychopharmacol. 2016 Feb;26(1):19-25. doi: 10.1089/cap.2015.0126. Epub 2016 Jan 8.

4.

The effect of psychostimulants on skeletal health in boys co-treated with risperidone.

Calarge CA, Schlechte JA, Burns TL, Zemel BS.

J Pediatr. 2015 Jun;166(6):1449-54.e1. doi: 10.1016/j.jpeds.2015.03.005. Epub 2015 Apr 8.

5.

Propranolol Attenuates Risperidone-Induced Trabecular Bone Loss in Female Mice.

Motyl KJ, DeMambro VE, Barlow D, Olshan D, Nagano K, Baron R, Rosen CJ, Houseknecht KL.

Endocrinology. 2015 Jul;156(7):2374-83. doi: 10.1210/en.2015-1099. Epub 2015 Apr 8.

6.

759C/T Variants of the Serotonin (5-HT2C) Receptor Gene and Weight Gain in Children and Adolescents in Long-Term Risperidone Treatment.

Del Castillo N, Zimmerman M B, Tyler B, Ellingrod VL, Calarge C.

Clin Pharmacol Biopharm. 2013 Jun 29;2(2):110.

7.

Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.

Calarge CA, Nicol G, Schlechte JA, Burns TL.

J Child Adolesc Psychopharmacol. 2014 Apr;24(3):120-9. doi: 10.1089/cap.2013.0126.

8.

Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges.

Glennon J, Purper-Ouakil D, Bakker M, Zuddas A, Hoekstra P, Schulze U, Castro-Fornieles J, Santosh PJ, Arango C, Kölch M, Coghill D, Flamarique I, Penzol MJ, Wan M, Murray M, Wong IC, Danckaerts M, Bonnot O, Falissard B, Masi G, Fegert JM, Vicari S, Carucci S, Dittmann RW, Buitelaar JK; PERS Consortium.

Eur Child Adolesc Psychiatry. 2014 Dec;23(12):1149-60. doi: 10.1007/s00787-013-0498-3. Epub 2013 Dec 15.

9.

Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents.

Calarge CA, Ivins SD, Motyl KJ, Shibli-Rahhal AA, Bliziotes MM, Schlechte JA.

Ther Adv Psychopharmacol. 2013 Oct;3(5):278-93. doi: 10.1177/2045125313487548.

10.

Iron deficiency in pediatric patients in long-term risperidone treatment.

Calarge CA, Ziegler EE.

J Child Adolesc Psychopharmacol. 2013 Mar;23(2):101-9. doi: 10.1089/cap.2012.0046. Epub 2013 Mar 12.

11.

Rate of weight gain and cardiometabolic abnormalities in children and adolescents.

Calarge CA, Xie D, Fiedorowicz JG, Burns TL, Haynes WG.

J Pediatr. 2012 Dec;161(6):1010-5. doi: 10.1016/j.jpeds.2012.05.051. Epub 2012 Jun 26.

12.

Correlates of weight gain during long-term risperidone treatment in children and adolescents.

Calarge CA, Nicol G, Xie D, Zimmerman B.

Child Adolesc Psychiatry Ment Health. 2012 May 29;6(1):21. doi: 10.1186/1753-2000-6-21.

13.

Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.

Motyl KJ, Dick-de-Paula I, Maloney AE, Lotinun S, Bornstein S, de Paula FJ, Baron R, Houseknecht KL, Rosen CJ.

Bone. 2012 Feb;50(2):490-8. doi: 10.1016/j.bone.2011.08.005. Epub 2011 Aug 11.

14.

Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth.

Pringsheim T, Panagiotopoulos C, Davidson J, Ho J; CAMESA guideline group.

J Can Acad Child Adolesc Psychiatry. 2011 Aug;20(3):218-33. Erratum in: J Can Acad Child Adolesc Psychiatry. 2011 August;20(3):1–2..

15.

Predictors of risperidone and 9-hydroxyrisperidone serum concentration in children and adolescents.

Calarge CA, Miller del D.

J Child Adolesc Psychopharmacol. 2011 Apr;21(2):163-9. doi: 10.1089/cap.2010.0038. Epub 2011 Apr 12.

16.

Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.

Hoekstra PJ, Troost PW, Lahuis BE, Mulder H, Mulder EJ, Franke B, Buitelaar JK, Anderson GM, Scahill L, Minderaa RB.

J Child Adolesc Psychopharmacol. 2010 Dec;20(6):473-7. doi: 10.1089/cap.2009.0071.

17.

Iron status in toddlerhood predicts sensitivity to psychostimulants in children.

Turner CA, Xie D, Zimmerman BM, Calarge CA.

J Atten Disord. 2012 May;16(4):295-303. doi: 10.1177/1087054710385067. Epub 2010 Oct 26.

18.

Management of antipsychotic-related weight gain.

Maayan L, Correll CU.

Expert Rev Neurother. 2010 Jul;10(7):1175-200. doi: 10.1586/ern.10.85. Review.

19.

First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

Panagiotopoulos C, Ronsley R, Elbe D, Davidson J, Smith DH.

J Can Acad Child Adolesc Psychiatry. 2010 May;19(2):124-37.

20.

A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys.

Calarge CA, Zimmerman B, Xie D, Kuperman S, Schlechte JA.

J Clin Psychiatry. 2010 Mar;71(3):338-47. doi: 10.4088/JCP.08m04595gre.

Supplemental Content

Support Center